• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Harnessing Indication-Specific Data on Biosimilars


Professionals explore the importance of indication-specific data in gastroenterology.

This is a video synopsis/summary of a panel discussion involving Ryan Haumschild, PharmD, MS, MBA; Alice B. Gottlieb, MD, PhD; Bincy Abraham, MD, MS; Jamie T. Brogan, APRN; and Vibeke Strand, MD.

Haumschild asks Abraham to reemphasize the value of indication-specific data in gastroenterology for biosimilars. Abraham says indication-specific data are highly valued because gastroenterology uses much higher and different dosing schedules than other specialties. Seeing data with the doses used specifically in inflammatory bowel disease increases confidence in recommending a switch vs a biosimilar lacking those data.

Gottlieb agrees that indication-specific data are important in dermatology given different dosing and patient factors in psoriasis vs rheumatoid arthritis.

They discussed how differences like citrate formulation affect patient preference and tolerability. The variations between biosimilars must be considered to choose optimal products. Indication-specific data provide confidence for providers when they are selecting among multiple biosimilar options.

Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.

Related Videos
Video 2 - "Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer"
ateyeh soroush
dr kathy zackowski
dr mitzi joi williams
Related Content
© 2024 MJH Life Sciences
All rights reserved.